Tolerability of oral bisphosponates in patients with osteoporosis and other osteopathies;Tolerabilidad digestiva de los bisfosfonatos orales en pacientes con osteoporosis y otras osteopatias medicas

Medicina

Volumn 57, Issue SUPPL. 1, 1997, Pages 114-118

  Spivacow, Rodolfo ^a   Roldán, Emilio J A ^b   Zanetti, Daniel ^b   Piccinni, Enrique ^b   Zanchetta, José R ^a  

^a Instituto de Investigaciones Metabolicas   (Argentina)

^b Gador SA   (Argentina)

Author keywords

Bisfosfonatos; Esofagitis; Gastritis; Solubilidad

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; OLPADRONIC ACID; PAMIDRONIC ACID;

BONE DISEASE; DRUG FORMULATION; DRUG TOLERABILITY; HUMAN; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; SHORT SURVEY;

ADULT; BONE DISEASES, METABOLIC; DIPHOSPHONATES; DRUG TOLERANCE; GASTRIC MUCOSA; GASTROINTESTINAL DISEASES; HUMANS; OSTEOPOROSIS; SOLUBILITY;

EID: 0030802751     PISSN: 00257680     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Lufkin EG, Argueta R, Whitaker MD, et al. Pamidronate: An unrecognized problem in gastrointestinal tolerability. Osteoporosis Int 1994; 4: 320-2.
2. Spivacow FR, Zanchetta JR, Kerzberg EM, Fngeri A, Flasché R, Roldán EJA. Tolerability of oral pamidronate in elderly patients with osteoporosis and other bone diseases. Curr Ther Res 1996; 57: 123-130.
3. Freedholm D, Emkey R, Cummings DC, Averbuch S, Santora A, Lombardi A, et al. Safety and tolerability of oral alendronate in the treatment of postmenopausal osteoporosis. Osteoporosis Int 1996; 6(supl 1): 261.
4. Twiss IM, de Water R, den Hartigh J, et al. Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport. J Pharmac Sci 1994; 83: 699-703.
5. Lin JH. Bisphosphonates: A review of their pharmacokinetic properties. Bone 1996; 18: 75-85.
6. Roldán EJA, Mondelo N, Piccinni E, Peluffo V, Montuori E. Olpadronic acid Sodium Salt - Treatment for Paget's bone disease, treatment for osteoporosis. Drug of the Future 1995; 20: 1123-7.
7. Escobar SO, Palacios A, Paglia N, Roldán EJA. Influencia de la molaridad y solubilidad de soluciones de ácidos fosfónicos en la toxicidad cutánea inducida en ratones Balb C. Actas del I Congreso Argentino de Osteoporosis, Buenos Aires, noviembre 1994.
8. Blank MA, Ems BL, Gibson GW, Myers WR, Phipps RJ, Smith PN. In a novel preclinical model primary amino bisphosphonates show greater potential for gastric effects than pyridinyl bisphosphonate. Bone 1995; 17: 598.
9. Roldán EJA, Araujo G, Quattrocchi O, Zanetti D, Piccinni E, Pérez Lloret A. Influence of the particle size of oral pamidronate (APD) on digestive tolerability. Acta Physiol Pharmacol et Therap LatinoAm 46: 274, 1996.
10. Coleman RE, Dirix LY, Dodwell D et al. Phase I/II evaluation of effervescent and enteric coated oral pamidronate for bone metastases. EurJ Cancer 1991 27: 945-6.
11. Vega E, Mautalen C, Roldán EJA, Pérez Lloret A. Preliminary study of increasing oral doses of Dimethyl APD on bone metabolism dynamics and safety profile. Drugs Exptl Clin Res 1994; 20: 103-8.
12. Fromm GA, Vega E, Galich AM et al. Side effects verified during the treatment of 228 cases of involutional osteoporosis with pamidronate. Bone Miner 1992 17(suppl): S17.